Stock Analysis, Dividends, Split History

VSAR / Versartis, Inc.. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price1.40
Volume258,000.00
Market Cap ($M)52.55
Enterprise Value ($M)-15.23
Book Value ($M)68.94
Book Value / Share1.90
Price / Book0.76
NCAV ($M)57.10
NCAV / Share1.58
Price / NCAV0.92
Share Statistics
Common Shares Outstanding 36,058,138
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 35,938,126
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.03
Return on Assets (ROA)-0.41
Return on Equity (ROE)-0.56
Balance Sheet (mrq) ($M)
Assets80.30
Liabilities11.36
Quick Ration/a
Current Ratio16.95
Income Statement (mra) ($M)
Revenues40,000,000.00
Contracts Revenue40,000,000.00
Operating Income-84.48
Net Income-84.98
Earnings Per Share Basic And Diluted-2.41
Earnings Per Share Diluted-2.41
Earnings Per Share Basic-2.41
Cash Flow Statement (mra) ($M)
Cash From Operations-116.29
Cash from Investing-6.69
Cash from Financing-116.29
Identifiers and Descriptors
CUSIP92529L102
Central Index Key (CIK)1513818
Related CUSIPS
92529L952 92529L902

Split History

Stock splits are used by Versartis, Inc.. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
VSAR : Versartis Stock Analysis and Research Report

2017-11-07 - Asif

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing a novel long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency, or GHD, an orphan disease. A key limitation to current recombinant human growth hormone, or rhGH, products is that they impose the burden of daily injections over multiple years, often resulting in poor adherence, which in turn can lead to suboptimal treatment outcomes in GHD patients. Despite this limitation, global annual sales from currently marketed rhGH products have grown to more than $3.0 billion in 2015. Based on market research, the company believe that the market for rhGH products can continue to grow up to $4.0 billion following the launch of long-acting rhGH therapies. Somavaratan is a fusion protein consisting of rhGH and a proprietary half-life extension technology known as XTEN®. Somavaratan is intended to reduce the burden of daily treatment by requiring significa...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Acadia Pharmaceuticals: What Investors Can Expect From This Grower?

2018-06-21 seekingalpha
Acadia shares have been trading on a downtrend for the past 52 weeks. The market is apprehensive of the uncertain nature of the lead molecule (pimavanserin) due to its unknown mechanism. (85-1)

Institutional Top Ideas: Cormorant Asset Management

2018-06-16 seekingalpha
Cormorant Asset Management has overweighted its top 5 positions (especially first 3) and a relatively high turnover compared to other funds we´ve looked at. (233-1)

Institutional Top Ideas: EcoR1 Capital

2018-06-12 seekingalpha
Returns for EcoR1 Capital are quite impressive. It is significantly differentiated from peers with a higher percent of the portfolio in its top 10 positions and a higher turnover rate. (204-2)

Coty, Avon Drop into Monday’s 52-Week Low Club

2018-06-04 247wallst
June 4, 2018: Here are four stocks trading with heavy volume among 83 equities making new 52-week lows in Monday’s session. On the NYSE advancers led decliners by about 2.21 to 1 and on the Nasdaq, advancers led decliners by about 2.09 to 1. (76-2)

Institutional Top Ideas Series: Ra Capital Management

2018-05-10 seekingalpha
Today's fund in the spotlight, Ra CapitalManagement, has the best performance of the funds we´ve looked at so far. (190-2)

CUSIP: 92529L102